Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Celularity Inc. - Class A Common Stock (NQ:CELU)

1.770 +0.170 (+10.62%)
Delayed Quote Updated: 12:45 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Celularity Inc. - Class A Common Stock

News headline image
Celularity Announces Naveen Jain to Join Board of Directors
Viome founder and CEO brings a consumer-focused vision for bringing regenerative therapies to more people and advancing proactive health 
From Celularity Inc.
Via GlobeNewswire
News headline image
Celularity Announces Over $10 Million Initial Financing Closing as Part of Up to $28 Million Recapitalization to Accelerate Growth Following Significant Operating Improvements
From Celularity Inc.
Via GlobeNewswire
News headline image
Celularity and MuseCell Innovations® Announce U.S. Manufacturing Collaboration for the Dezawa MuseCell® Platform
From MuseCell Innovations
Via Business Wire
News headline image
Celularity Provides Update Regarding Nasdaq Listing Compliance
From Celularity Inc.
Via GlobeNewswire
News headline image
Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies
From Celularity Inc.
Via GlobeNewswire
News headline image
Celularity Presents Data of The Effect of Its T-Cell Platform on Multiple Hematological And Solid Tumors at the American Society of Clinical Oncology (ASCO) Annual Meeting
Company presents results from in vivo studies of PT-CD16VS, a genetically modified allogeneic cell therapy derived from human placental circulating T (P-T) cells, in combination with various monoclonal... 
From Celularity Inc.
Via GlobeNewswire
News headline image
Celularity Inc. to Host Investor and Analyst Research & Development Day
Event Will Be Hosted On-site and Aired Virtually Highlighting Research, Clinical and Commercial Progress 
From Celularity Inc.
Via GlobeNewswire
News headline image
Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial Products
From Celularity Inc.
Via GlobeNewswire
News headline image
Celularity and CH Trading Group Announce Product Distribution Agreement with Tamer Group to be the Exclusive Distributor for the Kingdom of Saudi Arabia
From Celularity Inc.
Via Business Wire
News headline image
Celularity and CH Trading Group Announce Territory Distribution Agreement for the Middle East
From Celularity Inc.
Via Business Wire
CIRCLE H INTERNATIONAL (Ⓗ®™) SHARIA ADVISORY COUNCIL ISSUES UNPRECEDENTED FATWA FOR CONDITIONAL PERMITTED USE OF STEM CELLS, EXOSOMES, AND BIOMATERIALS IN RESEARCH, CLINICAL TRIALS AND TREATMENT
New York, New York, United States - 12-20-2022 (PR Distribution™) - 
Via PR Distribution
Topics Religion
News headline image
Celularity Announces Halal Certification of its Advanced Cellular Therapeutics, Biomaterial Products and Business Model
From Celularity Inc.
Via Business Wire
News headline image
Celularity CEO Robert J. Hariri, M.D., Ph.D., Addresses FII Conference on “The Science and Technology for Extending Healthy Human Lifespan”
From Celularity, Inc.
Via Business Wire
How Aging-Related Conditions Are Increasing The Treatment Burden For Older Patients
Via FinancialNewsMedia
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.